{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:44:07Z","timestamp":1762548247050,"version":"build-2065373602"},"reference-count":79,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001845","name":"Scleroderma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001845","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007150","name":"United Therapeutics Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.beha.2025.101626","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T11:42:49Z","timestamp":1746186169000},"page":"101626","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advancing MSC therapy: The next generation of potent mesenchymal stromal cells for systemic autoimmune rheumatic diseases"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2256-9068","authenticated-orcid":false,"given":"Hulya","family":"Bukulmez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin B.","family":"Highland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rujman","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary S.","family":"Gilkeson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven N.","family":"Emancipator","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2025.101626_bib1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41536-019-0083-6","article-title":"Mesenchymal stem cell perspective: cell biology to clinical progress","volume":"4","author":"Pittenger","year":"2019","journal-title":"NPJ Regen Med"},{"issue":"7","key":"10.1016\/j.beha.2025.101626_bib2","doi-asserted-by":"crossref","first-page":"695","DOI":"10.5966\/sctm.2014-0291","article-title":"Body management: mesenchymal stem cells control the internal regenerator","volume":"4","author":"Caplan","year":"2015","journal-title":"Stem Cells Transl Med"},{"issue":"2","key":"10.1016\/j.beha.2025.101626_bib3","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.imlet.2015.06.005","article-title":"The MSC curtain that stops the immune system","volume":"168","author":"Caplan","year":"2015","journal-title":"Immunol Lett"},{"issue":"4","key":"10.1016\/j.beha.2025.101626_bib4","first-page":"557","article-title":"Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use","volume":"16","author":"Lazarus","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.beha.2025.101626_bib5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00000441-200208000-00001","article-title":"Modern academic medicine","volume":"324","author":"DuBois","year":"2002","journal-title":"Am J Med Sci"},{"issue":"5","key":"10.1016\/j.beha.2025.101626_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2016.26","article-title":"Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway","volume":"5","author":"Oon","year":"2016","journal-title":"Clin Transl Immunology"},{"issue":"11","key":"10.1016\/j.beha.2025.101626_bib7","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00109-012-0907-y","article-title":"The multifaceted balance of TNF-alpha and type I\/II interferon responses in SLE and RA: how monocytes manage the impact of cytokines","volume":"90","author":"Smiljanovic","year":"2012","journal-title":"J Mol Med (Berl)."},{"issue":"1","key":"10.1016\/j.beha.2025.101626_bib8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13075-019-1878-y","article-title":"High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus","volume":"21","author":"Oke","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.beha.2025.101626_bib9","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1182\/blood-2002-01-0176","article-title":"Cytokine and chemokine profiles in autologous graft-versus-host disease (GVHD): interleukin 10 and interferon gamma may be critical mediators for the development of autologous GVHD","volume":"100","author":"Miura","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2025.101626_bib10","first-page":"470","article-title":"Expressions of type I-III interferons in Sjogren's syndrome and non-Sjogren's dry eye","volume":"67","author":"Su","year":"2024","journal-title":"Ophthalmic Res"},{"issue":"5","key":"10.1016\/j.beha.2025.101626_bib11","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jbspin.2009.03.012","article-title":"Interferons and autoimmune disorders","volume":"76","author":"Meyer","year":"2009","journal-title":"Jt Bone Spine"},{"issue":"6\u20137","key":"10.1016\/j.beha.2025.101626_bib12","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.biochi.2007.04.013","article-title":"Dendritic cells and interferon-mediated autoimmunity","volume":"89","author":"Gottenberg","year":"2007","journal-title":"Biochimie"},{"issue":"3","key":"10.1016\/j.beha.2025.101626_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003475","article-title":"Differential regulation of the interferon response in systemic lupus erythematosus distinguishes patients of Asian ancestry","volume":"9","author":"Rector","year":"2023","journal-title":"RMD Open"},{"issue":"7","key":"10.1016\/j.beha.2025.101626_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076578","article-title":"Advances in the pathogenesis and treatment of systemic lupus erythematosus","volume":"24","author":"Accapezzato","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.beha.2025.101626_bib15","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/s41590-024-01898-7","article-title":"The immunology of systemic lupus erythematosus","volume":"25","author":"Tsokos","year":"2024","journal-title":"Nat Immunol"},{"key":"10.1016\/j.beha.2025.101626_bib16","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1146\/annurev-med-043021-032611","article-title":"Systemic lupus erythematosus: new diagnostic and therapeutic approaches","volume":"74","author":"Lazar","year":"2023","journal-title":"Annu Rev Med"},{"issue":"2","key":"10.1016\/j.beha.2025.101626_bib17","doi-asserted-by":"crossref","DOI":"10.1186\/ar4520","article-title":"Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study","volume":"16","author":"Wang","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.beha.2025.101626_bib18","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.3727\/096368911X582769c","article-title":"Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience","volume":"22","author":"Wang","year":"2013","journal-title":"Cell Transplant"},{"issue":"11","key":"10.1016\/j.beha.2025.101626_bib19","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s10067-014-2754-4","article-title":"Allogeneic mesenchymal stem cell transplantation for lupus nephritis patients refractory to conventional therapy","volume":"33","author":"Gu","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.beha.2025.101626_bib20","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s10238-016-0427-0","article-title":"Long-term safety of umbilical cord mesenchymal stem cells transplantation for systemic lupus erythematosus: a 6-year follow-up study","volume":"17","author":"Wang","year":"2017","journal-title":"Clin Exp Med"},{"issue":"1","key":"10.1016\/j.beha.2025.101626_bib21","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/s13287-018-1053-4","article-title":"Safety analysis in patients with autoimmune disease receiving allogeneic mesenchymal stem cells infusion: a long-term retrospective study","volume":"9","author":"Liang","year":"2018","journal-title":"Stem Cell Res Ther"},{"issue":"8","key":"10.1016\/j.beha.2025.101626_bib22","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1136\/annrheumdis-2017-211073","article-title":"A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis","volume":"76","author":"Deng","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6 Pt 2","key":"10.1016\/j.beha.2025.101626_bib23","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.lpm.2016.05.002","article-title":"Stem cell transplantation and mesenchymal cells to treat autoimmune diseases","volume":"45","author":"Tyndall","year":"2016","journal-title":"Presse Med"},{"issue":"10","key":"10.1016\/j.beha.2025.101626_bib24","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1093\/rheumatology\/kel158","article-title":"Adult stem cells in the treatment of autoimmune diseases","volume":"45","author":"van Laar","year":"2006","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.beha.2025.101626_bib25","article-title":"Pathophysiology of systemic sclerosis","volume":"50","author":"Thoreau","year":"2021","journal-title":"Presse Med"},{"issue":"10373","key":"10.1016\/j.beha.2025.101626_bib26","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0140-6736(22)01692-0","article-title":"Systemic sclerosis","volume":"401","author":"Volkmann","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.beha.2025.101626_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2023.105627","article-title":"Type 1 interferons: a target for immune-mediated inflammatory diseases (IMIDs)","volume":"91","author":"Mathian","year":"2024","journal-title":"Jt Bone Spine"},{"issue":"2","key":"10.1016\/j.beha.2025.101626_bib28","first-page":"197","article-title":"Interferon-gamma induces interleukin-6 production and alpha-smooth muscle actin expression in systemic sclerosis fibroblasts","volume":"23","author":"Rokni","year":"2024","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"10.1016\/j.beha.2025.101626_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2018.12.018","article-title":"Type I interferon dysregulation in systemic sclerosis","volume":"132","author":"Skaug","year":"2020","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.beha.2025.101626_bib30","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1513\/AnnalsATS.202301-056OC","article-title":"Tocilizumab in patients with systemic sclerosis-associated interstitial lung disease: a systematic review and meta-analysis","volume":"21","author":"Ghazipura","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.beha.2025.101626_bib31","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211066686","article-title":"The role of antifibrotic therapies in the treatment of systemic sclerosis-associated interstitial lung disease","volume":"14","author":"Boleto","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"1","key":"10.1016\/j.beha.2025.101626_bib32","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13075-025-03524-9","article-title":"Trajectories of forced vital capacity in patients with systemic sclerosis-associated interstitial lung disease","volume":"27","author":"Distler","year":"2025","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.beha.2025.101626_bib33","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","article-title":"Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial","volume":"9","author":"Highland","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.beha.2025.101626_bib34","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ccm.2019.05.001","article-title":"Pulmonary manifestations of systemic sclerosis and mixed connective tissue disease","volume":"40","author":"Perelas","year":"2019","journal-title":"Clin Chest Med"},{"issue":"2","key":"10.1016\/j.beha.2025.101626_bib35","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1164\/rccm.202306-1113ST","article-title":"Treatment of systemic sclerosis-associated interstitial lung disease: evidence-based recommendations. An official American thoracic society clinical practice guideline","volume":"209","author":"Raghu","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.beha.2025.101626_bib36","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1093\/rheumatology\/kev117","article-title":"Haematopoietic stem cell transplantation for poor-prognosis systemic sclerosis","volume":"54","author":"van Laar","year":"2015","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.beha.2025.101626_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102755","article-title":"Mesenchymal stromal cells for systemic sclerosis treatment","volume":"20","author":"Farge","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"9","key":"10.1016\/j.beha.2025.101626_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9093023","article-title":"Clinical efficacy and safety of injection of stromal vascular fraction derived from autologous adipose tissues in systemic sclerosis patients with hand disability: a proof-of-concept trial","volume":"9","author":"Park","year":"2020","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.beha.2025.101626_bib39","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1046\/j.1365-2141.2002.03895.x","article-title":"Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study","volume":"119","author":"Farge","year":"2002","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.beha.2025.101626_bib40","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1007\/s11033-023-08277-9","article-title":"Bone marrow derived mesenchymal stem cells therapy for rheumatoid arthritis - a concise review of past ten years","volume":"50","author":"Arshad","year":"2023","journal-title":"Mol Biol Rep"},{"issue":"8","key":"10.1016\/j.beha.2025.101626_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/cells9081852","article-title":"Mesenchymal stem\/stromal cells for rheumatoid arthritis treatment: an update on clinical applications","volume":"9","author":"Lopez-Santalla","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.beha.2025.101626_bib42","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ebiom.2019.08.073","article-title":"Meta-analysis of preclinical studies of mesenchymal stromal cells to treat rheumatoid arthritis","volume":"47","author":"Liu","year":"2019","journal-title":"EBioMedicine"},{"issue":"9","key":"10.1016\/j.beha.2025.101626_bib43","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/sctm.18-0031","article-title":"Intravenous infusion of umbilical cord blood-derived mesenchymal stem cells in rheumatoid arthritis: a phase Ia clinical trial","volume":"7","author":"Park","year":"2018","journal-title":"Stem Cells Transl Med"},{"issue":"6","key":"10.1016\/j.beha.2025.101626_bib44","doi-asserted-by":"crossref","DOI":"10.1186\/ar3187","article-title":"Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis","volume":"12","author":"Liu","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.beha.2025.101626_bib45","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/1479-5876-9-181","article-title":"Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells","volume":"9","author":"Ra","year":"2011","journal-title":"J Transl Med"},{"issue":"1","key":"10.1016\/j.beha.2025.101626_bib46","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10067-011-1816-0","article-title":"Allogeneic mesenchymal stem cells transplantation in patients with refractory RA","volume":"31","author":"Liang","year":"2012","journal-title":"Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.beha.2025.101626_bib47","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/17460751.2024.2443352","article-title":"Allogeneic bone marrow derived clonal mesenchymal stromal cells in refractory rheumatoid arthritis: a pilot study","volume":"19","author":"Jamshidi","year":"2024","journal-title":"Regen Med"},{"issue":"10","key":"10.1016\/j.beha.2025.101626_bib48","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1136\/annrheumdis-2020-217798","article-title":"Combination of human umbilical cord mesenchymal stem (stromal) cell transplantation with IFN-gamma treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis","volume":"79","author":"He","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.beha.2025.101626_bib49","article-title":"Therapeutic angiogenesis in Buerger's disease: reviewing the treatment landscape","volume":"3","author":"Ribieras","year":"2022","journal-title":"Ther Adv Respir Dis"},{"issue":"1","key":"10.1016\/j.beha.2025.101626_bib50","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/s13287-024-03957-0","article-title":"Mesenchymal stromal cell therapy (REGENACIP((R))), a promising treatment option in chronic limb threatening ischemia - a narrative review","volume":"15","author":"Desai","year":"2024","journal-title":"Stem Cell Res Ther"},{"issue":"12","key":"10.1016\/j.beha.2025.101626_bib51","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1002\/sctm.21-0197","article-title":"Phase IV postmarketing surveillance study shows continued efficacy and safety of Stempeucel in patients with critical limb ischemia due to Buerger's disease","volume":"10","author":"Gupta","year":"2021","journal-title":"Stem Cells Transl Med"},{"issue":"1","key":"10.1016\/j.beha.2025.101626_bib52","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s13287-021-02330-9","article-title":"Human bone marrow-derived, pooled, allogeneic mesenchymal stromal cells manufactured from multiple donors at different times show comparable biological functions in vitro, and in vivo to repair limb ischemia","volume":"12","author":"Thej","year":"2021","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"10.1016\/j.beha.2025.101626_bib53","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-73096-y","article-title":"Therapeutic angiogenesis using autologous adipose-derived regenerative cells in patients with critical limb ischaemia in Japan: a clinical pilot study","volume":"10","author":"Katagiri","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.beha.2025.101626_bib54","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/s13287-024-03924-9","article-title":"Mesenchymal stem cell therapy in eosinophilic granulomatosis with polyangiitis-related lower limb gangrene: a case report","volume":"15","author":"Wang","year":"2024","journal-title":"Stem Cell Res Ther"},{"issue":"2","key":"10.1016\/j.beha.2025.101626_bib55","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/1756-185X.12068","article-title":"Mesenchymal stem cell therapy unable to rescue the vision from advanced Behcet's disease retinal vasculitis: report of three patients","volume":"16","author":"Davatchi","year":"2013","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"10.1016\/j.beha.2025.101626_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2021.112941","article-title":"Human umbilical cord mesenchymal stem cells regulate CD54 and CD105 in vascular endothelial cells and suppress inflammation in Kawasaki disease","volume":"409","author":"Chen","year":"2021","journal-title":"Exp Cell Res"},{"issue":"2","key":"10.1016\/j.beha.2025.101626_bib57","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1272\/jnms.JNMS.2024_91-212","article-title":"Human adipose tissue-derived stem cells inhibit coronary artery vasculitis in a mouse model of Kawasaki disease","volume":"91","author":"Fukunaga","year":"2024","journal-title":"J Nippon Med Sch"},{"issue":"3","key":"10.1016\/j.beha.2025.101626_bib58","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.rdc.2016.03.010","article-title":"New treatment guidelines for Sjogren's disease","volume":"42","author":"Vivino","year":"2016","journal-title":"Rheum Dis Clin N Am"},{"issue":"1","key":"10.1016\/j.beha.2025.101626_bib59","article-title":"Effect of adipose tissue-derived stem cells therapy on clinical response in patients with primary Sjogren's syndrome","volume":"13","author":"Li","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.beha.2025.101626_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jtos.2023.11.007","article-title":"Allogeneic mesenchymal stem cell therapy for dry eye disease in patients with Sjogren's syndrome: a randomized clinical trial","volume":"31","author":"Moller-Hansen","year":"2024","journal-title":"Ocul Surf"},{"key":"10.1016\/j.beha.2025.101626_bib61","article-title":"Prognostic factors for clinical response in systemic lupus erythematosus patients treated by allogeneic mesenchymal stem cells","volume":"2019","author":"Wen","year":"2019","journal-title":"Stem Cell Int"},{"issue":"9","key":"10.1016\/j.beha.2025.101626_bib62","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1002\/sctm.17-0002","article-title":"Serum IFN-gamma predicts the therapeutic effect of mesenchymal stem cells transplantation in systemic lupus erythematosus patients","volume":"6","author":"Wang","year":"2017","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.beha.2025.101626_bib63","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3389\/fimmu.2015.00291","article-title":"Animal models of interferon signature positive lupus","volume":"6","author":"Zhuang","year":"2015","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.beha.2025.101626_bib64","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/art.40077","article-title":"Pathogenesis of diffuse alveolar hemorrhage in murine lupus","volume":"69","author":"Zhuang","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.beha.2025.101626_bib65","doi-asserted-by":"crossref","DOI":"10.1093\/stmcls\/sxae078","article-title":"Trained mesenchymal stromal cell-based therapy HXB-319 for treating diffuse alveolar hemorrhage in a pristane-induced murine model","volume":"43","author":"Bukulmez","year":"2025","journal-title":"Stem Cell"},{"key":"10.1016\/j.beha.2025.101626_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1473788","article-title":"Improving the therapeutic profile of MSCs: cytokine priming reduces donor-dependent heterogeneity and enhances their immunomodulatory capacity","volume":"16","author":"Valencia","year":"2025","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.beha.2025.101626_bib67","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000704","article-title":"Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE","volume":"9","author":"Kamen","year":"2022","journal-title":"Lupus Sci Med"},{"issue":"1","key":"10.1016\/j.beha.2025.101626_bib68","doi-asserted-by":"crossref","first-page":"7","DOI":"10.29235\/1814-6023-2022-19-1-7-18","article-title":"Immunological efficiency of the pooled mesenchymal stem cells of the olfactory lining of the nasal cavity for systemic lupuserythematosus treatment","volume":"19","author":"Rynda","year":"2022","journal-title":"Proceedings of the National Academy of Sciences of Belarus, Medical series (In Russ)"},{"issue":"2","key":"10.1016\/j.beha.2025.101626_bib69","article-title":"Allogeneic adipose-derived mesenchymal stromal cell transplantation for refractory lupus nephritis: results of a phase I clinical trial","volume":"70","author":"Ranjbar","year":"2022","journal-title":"Curr Res Transl Med"},{"issue":"10","key":"10.1016\/j.beha.2025.101626_bib70","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1177\/09612033221111957","article-title":"Safety and tolerability of bone marrow-derived mesenchymal stem cells in lupus animal models and a phase I clinical trial in humans","volume":"31","author":"Chun","year":"2022","journal-title":"Lupus"},{"issue":"11","key":"10.1016\/j.beha.2025.101626_bib71","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.3727\/096368914X685645","article-title":"Adipose tissue-derived mesenchymal stem cells induce expansion of interleukin-10-producing regulatory B cells and ameliorate autoimmunity in a murine model of systemic lupus erythematosus","volume":"24","author":"Park","year":"2015","journal-title":"Cell Transplant"},{"issue":"2","key":"10.1016\/j.beha.2025.101626_bib72","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/S2665-9913(21)00326-X","article-title":"Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: a single-centre, open-label, dose-escalation, proof-of-concept, phase 1\/2 study","volume":"4","author":"Farge","year":"2022","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"10.1016\/j.beha.2025.101626_bib73","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13287-022-02763-w","article-title":"Safety and efficacy of autologous, adipose-derived mesenchymal stem cells in patients with rheumatoid arthritis: a phase I\/IIa, open-label, non-randomized pilot trial","volume":"13","author":"Vij","year":"2022","journal-title":"Stem Cell Res Ther"},{"issue":"24","key":"10.1016\/j.beha.2025.101626_bib74","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1089\/scd.2013.0023","article-title":"Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: safety and efficacy","volume":"22","author":"Wang","year":"2013","journal-title":"Stem Cell Dev"},{"issue":"1","key":"10.1016\/j.beha.2025.101626_bib75","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/annrheumdis-2015-208918","article-title":"Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib\/IIa clinical trial","volume":"76","author":"Alvaro-Gracia","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.beha.2025.101626_bib76","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12967-018-1541-4","article-title":"Serum IFN-gamma levels predict the therapeutic effect of mesenchymal stem cell transplantation in active rheumatoid arthritis","volume":"16","author":"Yang","year":"2018","journal-title":"J Transl Med"},{"key":"10.1016\/j.beha.2025.101626_bib77","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.2147\/DDDT.S225613","article-title":"Efficacy and safety of umbilical cord mesenchymal stem cell therapy for rheumatoid arthritis patients: a prospective phase I\/II study","volume":"13","author":"Wang","year":"2019","journal-title":"Drug Des Dev Ther"},{"issue":"28","key":"10.1016\/j.beha.2025.101626_bib78","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000021222","article-title":"Cervus and cucumis peptides combined umbilical cord mesenchymal stem cells therapy for rheumatoid arthritis","volume":"99","author":"Qi","year":"2020","journal-title":"Medicine (Baltim)"},{"issue":"4","key":"10.1016\/j.beha.2025.101626_bib79","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jcyt.2017.12.009","article-title":"Intra-articular knee implantation of autologous bone marrow-derived mesenchymal stromal cells in rheumatoid arthritis patients with knee involvement: results of a randomized, triple-blind, placebo-controlled phase 1\/2 clinical trial","volume":"20","author":"Shadmanfar","year":"2018","journal-title":"Cytotherapy"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692625000313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692625000313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:40:11Z","timestamp":1762548011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692625000313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":79,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1521692625000313"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2025.101626","relation":{},"ISSN":["1521-6926"],"issn-type":[{"type":"print","value":"1521-6926"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancing MSC therapy: The next generation of potent mesenchymal stromal cells for systemic autoimmune rheumatic diseases","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2025.101626","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101626"}}